R-BIOPHARM AG AND GOLD STANDARD DIAGNOSTICS, CORP. ANNOUNCE STRATEGIC ALLIANCE

DAVIS, Calif.–(BUSINESS WIRE)–Gold Standard Diagnostics, Corp. (GSD) announced today a strategic alliance with R-Biopharm AG (Darmstadt, Germany) to collaborate on multiple technology and marketing initiatives that will leverage the companies’ respective strengths in expanding product offerings and geographic sales coverage.

Under this arrangement, GSD will be the exclusive distributor for R-Biopharm’s Clinical diagnostics products in the U.S. GSD has broad U.S. market coverage, through its national channel partners, in key clinical segments that include hospitals, POL’s and reference laboratories. This initiative expands GSD’s strategic vision of collaborating with technology leaders in bringing differentiated solutions to the market by adding content to GSD’s automated instrument platforms.

R-Biopharm has a broad portfolio of products, in multiple technology formats, which are complementary to GSD’s expertise in instrument development. This partnership will give R-Biopharm access to GSD products, including its instrumentation platforms and diagnostic test kits, to enhance their offering to their worldwide distribution network spread over 130 countries.

The two companies will also collaborate on several strategic projects for the U.S. and International markets that will leverage their respective strengths in developing transformative technologies that establish strong market niches. R-Biopharm’s network of subsidiaries and GSD’s select supplier base will present opportunities that will drive innovative concepts in delivering diagnostic solutions. GSD will also add to this partnership with its expertise in clearing products through the FDA.

John Griffiths, CEO of GSD, comments “We look forward to partnering with R-Biopharm, who has a strong track record of growing their business organically and through strategic acquisitions. RBIO is a globally-recognized leader in developing assays for the Clinical Diagnostics and Food & Feed testing markets. This alliance will also fast track innovation and investment in new technologies.”

Ralf Dreher, CEO of R-Biopharm, said “The partnership between R-Biopharm and Gold Standard Diagnostics will enable both companies to strengthen their position as solution providers in North America and the Global Market. GSD has an outstanding reputation in clinical business in the USA and can look back on many years of experience in laboratory equipment and automation. The synergy born out of this cooperation will set new standards in clinical diagnostics, which will also be highly beneficial for the customer.”

‍